Vitamin K and childhood cancer: analysis of individual patient data from six case–control studies by Roman, E et al.
Vitamin K and childhood cancer: analysis of individual patient data
from six case–control studies
E Roman*
,1, NT Fear
1, P Ansell
1, D Bull
2, G Draper
3, P McKinney
4, J Michaelis
5, SJ Passmore
3 and R von Kries
6
1Leukaemia Research Fund, Institute of Epidemiology, University of Leeds, 30 Hyde Terrace, Leeds LS2 9LN, UK;
2Cancer Epidemiology Unit, Imperial Cancer
Research Fund, Radcliffe Inﬁrmary, Oxford OX2 6HE, UK;
3Childhood Cancer Research Group, 57 Woodstock Road, Oxford OX2 6HJ, UK;
4Information
and Statistics Division, Trinity Park House, South Trinity Road, Edinburgh EH5 3SQ, UK;
5Institute of Medical Statistics and Documentation, Mainz,
Germany;
6Institute for Social Paediatrics and Adolescent Medicine, Munchen, Germany
To investigate the hypothesis that neonates who receive intramuscular vitamin K are at an increased risk of developing
cancer, particularly leukaemia, a pooled analysis of individual patient data from six case–control studies conducted in Great
Britain and Germany has been undertaken. Subjects comprised 2431 case children diagnosed with cancer before 15 years of
age and 6338 control children. The retrospective assessment of whether or not an individual baby received vitamin K is not
straightforward. In many cases no record was found in stored medical notes and two types of analysis were therefore
conducted; in the ﬁrst it was assumed that where no written record of vitamin K was found it had not been given, and in
the second, where no written record of administration was found, information on hospital policy and perinatal morbidity
was used to ‘impute’ whether or not vitamin K had been given. In the ﬁrst analysis, no association was found between
neonatal administration of intramuscular. vitamin K and childhood cancer: odds ratios adjusted for mode of delivery,
admission to special care baby unit and low birth weight were 1.09 (95% conﬁdence interval 0.92–1.28) for leukaemia and
1.05 (0.92–1.20) for other cancers. In the second analysis, the adjusted odds ratios increased to 1.21 (1.02–1.44) for
leukaemia and 1.10 (0.95–1.26) for other cancers. This shift did not occur in all studies, and when data from the hypothesis
generating Bristol study were excluded, the adjusted odds ratios for leukaemia became 1.06 (0.89–1.25) in the ﬁrst analysis
and 1.16 (0.97–1.39) when data on prophylaxis imputed from hospital policy and perinatal morbidity were used. We
conclude that whilst the broad nature of the diagnostic groups and the poor quality of some of the vitamin K data mean
that small effects cannot be entirely ruled out, our analysis provides no convincing evidence that intramuscular vitamin K is
associated with childhood leukaemia.
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The efﬁcacy of intramuscular (I.M.) vitamin K prophylaxis became
a controversial topic when Golding et al (1992) reported that chil-
dren who received it by this route were almost three times as likely
to develop leukaemia as children who received it orally or not at
all. Although subsequent studies failed to conﬁrm these ﬁndings
(Ekelund et al, 1993; Klebanoff et al, 1993; Olsen et al, 1994; Ansell
et al, 1996; von Kries et al, 1996; Roman et al, 1997; McKinney et
al, 1998; Parker et al, 1998; Passmore et al, 1998a,b), inconsisten-
cies in their results have left lingering doubts about the safety of
I.M. administration (Kaufman, 1999). As a consequence, a wide
variety of prophylactic policies now operate in hospitals through-
out the UK (Zipursky, 1996; Tripp and McNinch, 1998; Ansell et
al, 2001).
In order to investigate this topic in more depth, a pooled analy-
sis of individual patient data from the six major case–control
studies (Golding et al, 1992; Ansell et al, 1996; von Kries et al,
1996; Roman et al, 1997; McKinney et al, 1998; Parker et al,
1998; Passmore et al, 1998a) has been undertaken. The principal
aims were to use consistent deﬁnitions of exposure and potential
confounders to:
. determine whether or not there was an association between neo-
natal administration of I.M. vitamin K and childhood cancer,
particularly leukaemia;
. examine the degree to which the results varied with definition of
vitamin K exposure, potentially confounding factors (e.g. mode
of delivery), and hospital of birth.
Data description and methods
Details of the six studies contributing data to these analyses are
summarized in Table 1. Brieﬂy, all studies ascertained cases from
population-based cancer registries, four selecting controls from
populations of hospital births (Bristol, Oxford ICRF, Oxford
CCRG and Newcastle) and two from populations of children
who were alive and cancer-free at the age that their corresponding
case was diagnosed (Mainz and Scotland). The control group in the
Bristol study comprised every 300th birth entered into the hospital
delivery registers during the study period (1965 to 1987), whilst the
other ﬁve groups individually matched cases to one or more
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www.bjcancer.comcontrols on date of birth (month and year), and all but the
Newcastle group matched on sex. The differing control sources
meant that Oxford ICRF, Oxford CCRG and Newcastle individu-
ally matched controls to cases on hospital of birth, whereas
Mainz and Scotland matched on region of residence at the time
of diagnosis.
Studies that chose controls from hospital births visited fewer
hospitals than those that chose controls from the general childhood
population; the two extremes being Bristol and Mainz where the
number of hospitals visited were two and 162 respectively (Table
1). The proportion of cases whose obstetric notes were found
and abstracted varied from one study to another; being highest
for Bristol at 96% and lowest for Newcastle at 49%. Within the
two studies that selected controls from the general childhood
population, the proportions of cases and controls whose obstetric
notes were successfully traced were similar: 59 and 54% respectively
for Mainz and 83 and 84% respectively for Scotland. Analogous
ﬁgures cannot be calculated for the four studies that chose controls
from populations of hospital births.
For the purposes of the pooled analysis, each research group
provided anonymized individual computerized records containing
information on vitamin K exposure and an agreed list of variables
including: hospital of birth, date of birth, sex, gestational age, birth
weight, birth order, pregnancy order, mode of delivery, apgar score
and whether the baby was admitted to a special care baby unit or
nursery. Prior to the pooled analyses, individual published results
– using the same dataset, analytical procedures and adjusting vari-
ables as in the original study reports – were replicated and
conﬁrmed for all studies on receipt of their data (results not
shown).
THE POOLED DATASET
To standardize the data across the six studies, some subjects
included in the original analyses were excluded from the pooled
dataset (Table 2). The exclusions comprised cases diagnosed with
Langerhans cell histiocytosis (21 cases); benign neoplasms (other
than benign neoplasms of the central nervous system) (seven
cases); or any malignancy diagnosed during the ﬁrst month of life
(16 cases). Subjects (cases and controls) were also excluded if they
had Down’s syndrome (11 cases and ﬁve controls); were part of a
multiple birth (17 cases and 23 controls); had an unknown or
implausible birth weight (seven cases and six controls); an
unknown mode of delivery (two cases and two controls); or miss-
ing information on sex (19 controls). A further 57 controls were
excluded because the study centre/sex/year-of-birth strata to which
they were assigned contained no cases (see ‘The pooled analysis’).
Overall, 3% of cases and 2% of controls were excluded from the
pooled analysis, the ﬁnal dataset comprising 2431 cases and 6338
controls.
Certain amendments were made to the vitamin K exposure vari-
ables from three study centres following examination of the
computerized records (Table 2). The centres agreed all changes,
which arose as errors in the original data during computation of
imputed variables. Such inconsistencies could not be examined in
the population-based studies.
Information about vitamin K exposure is given in Table 3: the
frequencies differ from those in the published reports because of
the exclusions and amendments given in Table 2. When informa-
tion about vitamin K administration was not found in medical
records, all groups created an imputed prophylaxis variable. For
cases and controls, the central column gives the results of this
imputation and the ﬁnal column shows the total when medical
note and imputed data are combined.
The size of the ‘not recorded’ group, and the algorithms used to
impute prophylaxis (given/not given) and associated route of
administration (oral/intramuscular) varied from one centre to
another. Brieﬂy:
. Bristol, Oxford CCRG and Newcastle imputed when hospital
policy was reported to have been to give vitamin K to all babies
by a specified route (universal) and when reported to have been
to give I.M. vitamin K to ‘high risk’ neonates only (selective). In
the case of the latter, factors affecting perinatal morbidity (such
as mode of delivery, birth weight and admission to a special care
baby unit) were reviewed and vitamin K status assigned. Neo-
nates with a written or imputed record of having received oral
vitamin K were excluded from the Newcastle study.
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Table 1 Description of the six case-control studies included in the pooled analysis
Study centre
Bristol
1 Mainz
2 Oxford ICRF
3 Oxford CCRG
4 Scotland
5 Newcastle
6
Cases
Source Registry Registry Registry Registry Registry
a Registry
Place of diagnosis Britain
b Lower Saxony Britain Britain Scotland N. England
b
Place of birth Avon county Germany S. England
b England & Wales
b Britain N. England
b
Years of diagnosis 1971–91 1988–93 1957–92 1969–86 1991–94 1968–92
Years of birth 1965–87 1975–93 1943–92 1968–85 1976–94 1960–91
Age at diagnosis (years) 0–14 1 month–14 0–14 1–14 0–14 3 months–14
Controls
Source Hospital births General childhood
population
Hospital and
community births
Hospital births General childhood
population
Hospital births
Individually matched to cases on:
Date of birth 63 3 3 33
Sex 63 3 3 36
Hospital of birth 66 3 3 63
Residence at diagnosis 63
c 663
d 6
Alive at diagnosis 63 6 6 36
Data
Hospitals visited 2 162 3 20 70 26
Case notes abstracted (%) 195 (96) 272 (59) 367 (85) 597 (50) 417 (83) 664 (49)
Control notes abstracted (%) 558 (–) 334 (54) 734 (–) 667 (–) 777 (84) 3380 (–)
aRegistry plus notiﬁcation system established for the United Kingdom Childhood Cancer Study (UKCCS);
bparts of respective areas;
ctwo controls per
case for leukaemias, one from Lower Saxony and one from the same municipality;
dhealth board (15 in Scotland);
1Golding et al, 1992;
2von Kries et al,
1996;
3Ansell et al, 1996; Roman et al, 1997;
4Passmore et al, 1998a;
5McKinney et al, 1998;
6Parker et al, 1998.
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been given when current hospital staff reported that the policy
had, at the time the baby was born, been universal. Factors af-
fecting perinatal morbidity were not used to impute administra-
tion when hospital policy was reported to have been selective,
the advice of current hospital staff within the individual study
regions being that, in such circumstances, information about vi-
tamin K was only written down when it was, in fact, given.
. Mainz did not make a distinction between babies born at hos-
pitals with different vitamin K policies. Instead, details about vi-
tamin K exposure were derived from the closest child in the
birth register with the same mode of delivery and perinatal mor-
bidity as the index: it being assumed that the vitamin K status of
the study child was the same as the surrogate. If this was unin-
formative, an opinion about the likelihood of administration
was sought from medical personnel employed at the hospital
at the time of the study child’s birth (midwife, doctor or nurse).
If this could not be achieved, medical personnel employed else-
where were consulted.
THE POOLED ANALYSIS
As is evident from Tables 1–3, there are substantial differences
between the individual studies – with respect to their designs,
outcomes considered and exposure deﬁnitions. In the pooled
analysis, in order to use as much of the data as possible, the
original matching was ignored – instead all analyses took into
account study centre, sex and year of birth. However, because
of the large number of strata generated using logistic regression
(six study centres, two sexes and 56 years of birth – 672 strata
in total) the original controls provided by the centres were
frequency matched to cases on year of birth, sex and study
centre and relative risks estimated as odds ratios, using standard
conditional logistic techniques (Breslow and Day, 1980; Selvin,
1996). This approach, which was used by the Mainz group
(von Kries et al, 1996), produces similar results to a logistic
regression model but is computationally more efﬁcient (Neuha ¨u-
ser and Becher, 1997). In all analyses, risk is assessed in relation
to those known or imputed not to have received I.M. vitamin K
(not given or oral); for each odds ratio, approximate 95% conﬁ-
dence intervals (Wald test based) and two-sided tests of
statistical signiﬁcance were estimated. To test for variation
between centre speciﬁc odds ratios, tests for heterogeneity were
calculated based on the log likelihood ratio test statistic. All data
manipulation and statistical analyses were undertaken using the
statistical software package STATA (Release 6.0, STATACorp,
1999).
RESULTS
The number of exposed cases and odds ratios associated with
neonatal administration of intramuscular (I.M.) vitamin K are
given in Table 4, those based on the total data are in the top half
and those following the exclusion of data from the hypothesis
generating Bristol study in the bottom half. Odds ratios on the
left-hand side of the table are based on written records, assuming
that where no vitamin K record was found it was not given (the
route of administration, if not recorded, being based on reported
hospital policy). Those on the right-hand side are based on an
alternative method of imputation – those with no written record
being assigned to the most likely administration category on the
basis of information about perinatal morbidity and hospital
prophylaxis policies. In both instances, unadjusted odds ratios
and odds ratios adjusted for the potentially confounding affects
of mode of delivery, admission to special care baby unit and
low-birth weight are presented.
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Table 2 Pooled data – exclusions and vitamin K amendments
Study centre
Bristol
1 Mainz
2 Oxford ICRF
3 Oxford CCRG
4 Scotland
5 Newcastle
6,a
Subjects
Cases
Included (%) 178 (91) 262 (96) 361 (98) 594 (99) 389 (93) 647 (97)
Excluded (%) 17 (9) 10 (4) 6 (2) 3 (1) 28 (7) 17 (3)
Benign disease
b 11 – – – 6 11
Diagnosed 51 month 1 – 6 – 9 –
Down’s syndrome 2 2 – – 2 5
Multiple births 1 7 – – 9 –
Missing data
c 21 – 3 2 1
Controls
Included (%) 511 (92) 325 (97) 733 (99) 664 (99) 760 (98) 3345 (99)
Excluded (%) 47 (8) 9 (3) 1 (1) 3 (1) 17 (2) 35 (1)
Down’s syndrome – – – – 1 4
Multiple births 6 4 – – 13 –
Missing data
c –– 1 3 1 2 2
Unmatched
d 41 5 – – 2 9
Vitamin K amendments
e
Cases
Medical notes 2 (NKÞI.M.) not – 5 (I.M.Þoral) not –
2 (NKÞnone) 1 (I.M.Þnone)
Imputation 2 (NKÞoral) possible – 2 (not I.M.ÞI.M.) possible –
Controls to to
Medical notes – – 4 (I.M.Þoral) –
Imputation 2 (oralÞNK) check 2 (oralÞI.M.) 2 (not I.M.ÞI.M.) check –
aIn Newcastle, subjects with a record of having received oral vitamin K and subjects with imputed oral prophylaxis were excluded;
bLangerhans cell histiocytosis and benign neoplasms other than CNS;
cmissing birth weight, sex or mode of delivery;
dcontrols
who could not be matched to a case on year of birth, sex and study centre;
esubjects (nature of amendment) – NK=not known.
I.M.=intramuscular;
1Golding et al, 1992;
2von Kries et al, 1996;
3Ansell et al, 1996; Roman et al, 1997;
4Passmore et al, 1998a;
5McKinney et al, 1998;
6Parker et al, 1998.
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ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(1), 63–69When the classiﬁcation of prophylaxis (I.M. vitamin K given/not
given) was based solely on the fact that written evidence of admin-
istration was available from medical notes (with route imputed if
missing), the adjusted odds ratios for leukaemia and other cancers
were 1.09 (95% conﬁdence interval 0.92–1.28, P=0.315) and 1.05
(0.92–1.20, P=0.481) respectively (Table 4). When data on
prophylaxis were imputed from hospital policies and perinatal
morbidity using centre speciﬁc algorithms, the pooled odds ratios
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Table 3 Distribution of cases and controls included in the pooled analysis by vitamin K status assigned following medical note
abstraction and using study speciﬁc algorithms
Cases Controls
Medical notes Imputed Combined Medical notes Imputed Combined
Study centre Number (%) Number (%) Number (%) Number (%) Number (%) Number (%)
Bristol
1
Intramuscular 78 (44) 10 (26) 88 (49) 184 (36) 13 (28) 197 (39)
Oral 36 (20) 1 (3) 37 (21) 164 (32) 11 (23) 175 (34)
Not recorded
a 39 (22) 8 (21) 8 (5) 47 (9) 16 (34) 16 (3)
Not given 25 (14) 20 (51) 45 (25) 116 (23) 7 (15) 123 (24)
Mainz
2
Intramuscular 138 (53) 29 (39) 167 (64) 154 (47) 42 (36) 190 (60)
Oral 36 (14) 3 (4) 39 (15) 45 (14) 4 (3) 49 (15)
Not recorded
a 75 (29) – – 116 (36) – –
Not given 13 (5) 43 (57) 56 (21) 10 (3) 70 (60) 80 (25)
Oxford (ICRF)
3
Intramuscular 217 (60) 43 (35) 260 (72) 439 (60) 88 (41) 527 (72)
Oral 11 (3) 4 (3) 15 (4) 18 (2) 8 (4) 26 (4)
Not recorded
a 122 (34) – – 214 (29) – –
Not given 11 (3) 75 (61) 86 (24) 62 (9) 118 (55) 180 (25)
Oxford (CCRG)
4,b
Intramuscular 211 (36) 205 (62) 416 (70) 223 (34) 195 (59) 418 (63)
Oral 5 (1) – 5 (1) 4 (1) – 4 (1)
Not recorded
a 329 (55) – – 332 (50) – –
Not given 49 (8) 124 (38) 173 (29) 105 (16) 137 (41) 242 (36)
Scotland
5
Intramuscular 181 (47) 49 (27) 230 (59) 366 (49) 78 (23) 444 (58)
Oral 10 (3) – 10 (3) 29 (4) 2 (1) 31 (4)
Not recorded
a 182 (47) – – 343 (45) – –
Not given 16 (4) 133 (73) 149 (38) 22 (3) 263 (77) 285 (38)
Newcastle
6,b
Intramuscular 324 (50) 41 (19) 365 (56) 1576 (47) 267 (23) 1843 (55)
Oral excluded – – excluded – –
Not recorded
a 217 (34) – – 1178 (35) – –
Not given 106 (17) 176 (81) 282 (44) 591 (18) 911 (77) 1502 (45)
aNot recorded as given or not given in medical notes.
b133 cases and 133 controls were excluded by Oxford CCRG and 21 cases and 62 controls by
Newcastle because hospital policy was uncertain. These subjects are not included in the table.
1Golding et al, 1992;
2von Kries et al, 1996;
3Ansell et al,
1996; Roman et al, 1997;
4Passmore et al, 1998a;
5McKinney et al, 1998;
6Parker et al, 1998.
Table 4 Odds ratios (OR) and 95% conﬁdence intervals (CI) for intramuscular vitamin K, unadjusted and adjusted for mode of
delivery, admission to special care baby unit and low birth weight
Recorded in notes with route imputed,
if missing
Recorded in notes with route and
administration imputed, if missing
Total Exposed
OR
a (95% CI)
Exposed
OR
a (95% CI)
cases cases Unadjusted Adjusted
c cases Unadjusted Adjusted
c
Pooled data
Total cancers 2431 1149 1.08 (0.97–1.20) 1.07 (0.96–1.20) 1526 1.13 (1.02–1.26)* 1.14 (1.01–1.28)*
Leukaemia 935 455 1.13 (0.97–1.32) 1.09 (0.92–1.28) 605 1.25 (1.06–1.46)* 1.21 (1.02–1.44)*
ALL
b diagnosed 12–71 months 546 284 1.10 (0.90–1.34) 1.05 (0.85–1.29) 372 1.26 (1.02–1.55)* 1.20 (0.96–1.50)
Total minus leukaemia 1496 694 1.04 (0.91–1.18) 1.05 (0.92–1.20) 921 1.08 (0.95–1.22) 1.10 (0.95–1.26)
Pooled data – excluding the Bristol study
Total cancers 2253 1071 1.05 (0.94–1.17) 1.05 (0.94–1.18) 1438 1.10 (0.98–1.23) 1.11 (0.98–1.25)
Leukaemia 868 426 1.09 (0.93–1.29) 1.06 (0.89–1.25) 572 1.19 (1.01–1.41)* 1.16 (0.97–1.39)
ALL
b diagnosed 12–71 months 508 266 1.06 (0.86–1.30) 1.03 (0.83–1.27) 352 1.21 (0.97–1.49) 1.17 (0.93–1.47)
Total minus leukaemia 1385 645 1.02 (0.89–1.16) 1.04 (0.90–1.19) 866 1.05 (0.92–1.20) 1.08 (0.93–1.24)
*P50.05.
aOdds ratios and 95% conﬁdence intervals calculated using conditional logistic regression (frequency matched on year of birth, sex and study
centre).
bAcute lymphoblastic leukaemia.
cAdjusted for mode of delivery (normal vaginal, caesarean section, other), admission to special care baby unit
(no+unknown, yes), low birth weight (52501 g).
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becoming 1.21 (1.02–1.44, P=0.030) and 1.10 (0.95–1.26,
P=0.198) respectively. The odds ratios moved closer to unity when
the Bristol data were excluded, with none of the adjusted odds
ratios retaining their statistical signiﬁcance.
The increase in the magnitude of the pooled odds ratios when
administration was imputed on the grounds of hospital policy
stemmed principally from two centres – Bristol and Oxford CCRG
(Table 5). The adjusted odds ratios for leukaemia increased from
1.74 (0.84–3.60, P=0.136) to 2.57 (1.17–5.64, P=0.019) in the
Bristol data and from 0.89 (0.63–1.25, P=0.500) to 1.43 (1.00 to
2.06, P=0.052) in the Oxford CCRG data. In these centres, the
increase, although more pronounced, was not restricted to leukae-
mia: the odds ratios for cancers other than leukaemia increasing
from 1.19 (0.70–2.05, P=0.518) to 1.39 (0.79–2.46, P=0.257) in
the Bristol data and from 1.13 (0.85–1.49, P=0.408) to 1.35
(1.00–1.84, P=0.052) in the Oxford CCRG data. Systematic
changes of this type and magnitude were not evident for the four
remaining centres (Table 5).
The effect of stratifying by hospital of birth is examined in Table 6,
where odds ratios calculated using all available data and data from the
four studies that selected controls from hospital births (Bristol,
Oxford ICRF, Oxford CCRG and Newcastle) are presented. In gen-
eral, including hospital of birth in the analysis appears to exert little
effect: the adjusted odds ratios for leukaemia in the hospital-based
studies (excluding the Bristol data) being 1.06 (0.79–1.41) when it
was assumed that only babies with a written record of I.M. vitamin
K were exposed and 1.04 (0.73–1.49) when it was assumed that
babies for whom no written record was found, but for whom hospital
policy/perinatal morbidity suggested that they should have received it
by the I.M. route, were also classiﬁed as exposed.
DISCUSSION
Neonatal administration of 1 mg of I.M. vitamin K is known to be
effective in the prevention of both haemorrhagic disease in
neonates and late onset vitamin K deﬁciency bleeding (McNinch
and Tripp, 1991; Sutor et al, 1999; Zipursky, 1999). The efﬁcacy
of oral vitamin K is less certain and there have been reports that
late bleeding may occur in some healthy breast-fed babies in whom
no additional risk factors are identiﬁed (McNinch and Tripp, 1991;
Cornelissen et al, 1997; Sutor et al, 1999; Zipursky, 1999; Wariyar
et al, 2000). Controversy concerning prophylactic I.M. vitamin K is
not new – concerns having been expressed about the proven asso-
ciation between Synkavit (vitamin K2) and kernicterus,
documented cases of babies given oxytocics intended for the
mother, and the use of unlicensed oral preparations. Indeed, even
before the childhood cancer controversy such debate – enhanced
by the growth of the natural childbirth movement – had resulted
in marked variations between the policies of individual clinicians
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Table 5 Centre speciﬁc odds ratios (OR) and 95% conﬁdence intervals (CI) for intramuscular vitamin K,
unadjusted and adjusted for mode of delivery, admission to special care baby unit and low birth weight
Recorded in notes with route
imputed, if missing
Recorded in notes with route and
administration, imputed, if missing
OR
a (95% CI) OR
a (95% CI)
Study centre Unadjusted Adjusted
c Unadjusted Adjusted
c
Bristol
1
Total cancers 1.52 (1.00–2.31) 1.31 (0.82–2.09) 1.87 (1.21–2.88)* 1.69 (1.03–2.78)*
Leukaemia 1.91 (1.00–3.63)* 1.74 (0.84–3.60) 2.54 (1.29–5.00)* 2.57 (1.17–5.64)*
ALL
b diagnosed 12–71 months 2.04 (0.90–4.62) 1.48 (0.59–3.72) 2.50 (1.06–5.90)* 1.79 (0.65–4.91)
Total minus leukaemia 1.37 (0.84–2.23) 1.19 (0.70–2.05) 1.57 (0.95–2.58) 1.39 (0.79–2.46)
Mainz
2
Total cancers 1.11 (0.78–1.58) 1.02 (0.70–1.49) 1.11 (0.78–1.58) 1.03 (0.70–1.52)
Leukaemia 1.05 (0.68–1.62) 0.98 (0.62–1.57) 1.04 (0.67–1.62) 0.97 (0.59–1.59)
ALL
b diagnosed 12–71 months 1.50 (0.84–2.70) 1.38 (0.74–2.60) 1.76 (0.93–3.31) 1.65 (0.83–3.29)
Total minus leukaemia 1.13 (0.72–1.76) 1.02 (0.63–1.66) 1.18 (0.75–1.85) 1.09 (0.67–1.77)
Oxford (ICRF)
3
Total cancers 1.00 (0.76–1.32) 1.01 (0.76–1.34) 1.00 (0.74–1.36) 1.01 (0.74–1.39)
Leukaemia 1.13 (0.74–1.73) 1.09 (0.71–1.69) 1.15 (0.71–1.85) 1.11 (0.68–1.82)
ALL
b diagnosed 12–71 months 0.74 (0.43–1.28) 0.70 (0.39–1.24) 0.84 (0.45–1.56) 0.79 (0.41–1.52)
Total minus leukaemia 0.91 (0.65–1.26) 0.94 (0.67–1.33) 0.91 (0.63–1.31) 0.95 (0.65–1.39)
Oxford (CCRG)
4
Total cancers 1.07 (0.84–1.35) 1.04 (0.81–1.33) 1.35 (1.06–1.72)* 1.40 (1.08–1.82)*
Leukaemia 0.96 (0.69–1.34) 0.89 (0.63–1.25) 1.47 (1.06–2.06)* 1.43 (1.00–2.06)
ALL
b diagnosed 12–71 months 1.01 (0.69–1.49) 0.94 (0.63–1.41) 1.33 (0.86–1.85) 1.32 (0.84–2.02)
Total minus leukaemia 1.12 (0.85–1.48) 1.13 (0.85–1.49) 1.26 (0.95–1.66) 1.35 (1.00–1.84)
Scotland
5
Total cancers 0.94 (0.73–1.21) 0.94 (0.72–1.21) 1.03 (0.80–1.34) 1.02 (0.78–1.33)
Leukaemia 1.26 (0.87–1.82) 1.23 (0.84–1.79) 1.29 (0.87–1.89) 1.22 (0.82–1.82)
ALL
b diagnosed 12–71 months 1.01 (0.62–1.65) 1.06 (0.65–1.74) 0.91 (0.54–1.52) 0.91 (0.54–1.53)
Total minus leukaemia 0.78 (0.58–1.06) 0.79 (0.58–1.08) 0.91 (0.67–1.24) 0.92 (0.67–1.26)
Newcastle
6
Total cancers 1.12 (0.93–1.35) 1.16 (0.95–1.43) 1.02 (0.85–1.23) 1.05 (0.85–1.30)
Leukaemia 1.12 (0.82–1.51) 1.18 (0.85–1.65) 1.03 (0.77–1.39) 1.10 (0.78–1.55)
ALL
b diagnosed 12–71 months 1.15 (0.78–1.68) 1.16 (0.77–1.75) 1.26 (0.86–1.25) 1.32 (0.86–2.03)
Total minus leukaemia 1.13 (0.90–1.42) 1.16 (0.90–1.49) 1.02 (0.81–1.28) 1.02 (0.79–1.32)
*P50.05.
aOdds ratio and 95% conﬁdence intervals calculated using conditional logistic regression (frequency matched on year
of birth, sex and study centre).
bAcute lymphoblastic leukaemia.
cAdjusted for mode of delivery (normal vaginal, caesarean
section, other), admission to special care baby unit (no+unknown, yes), low birth weight (52501 g).
1Golding et al, 1992;
2von Kries et al, 1996;
3Ansell et al, 1996; Roman et al, 1997;
4Passmore et al, 1998a;
5McKinney et al, 1998;
6Parker et al, 1998.
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The Bristol case-control study (Golding et al, 1992) was initiated
following the unexpected associations observed in a national cohort
study between childhood cancer and maternal exposure to pethidine
during labour and neonatal exposure to prophylactic drugs, princi-
pally vitamin K (route unspeciﬁed) (Golding et al, 1990). The
ﬁndings of Golding et al (1992), suggesting that children who
received I.M. vitamin K were almost three times as likely to develop
leukaemia as those given it orally or not at all, fuelled existing debate
and as a consequence, throughout the UK at least, vitamin K policies
were reviewed and modiﬁed, a number of epidemiological investiga-
tions initiated and laboratory-based tests and trials of alternative oral
preparations and regimens undertaken.
Many of the subsequent epidemiological studies were, like the
Bristol study, based on information obtained from medical records.
A problem common to all was that retrospective assessment of
neonatal exposure to vitamin K is not straightforward, the main
reasons being:
. written records about prophylaxis can be found in several places
including mothers’ obstetric notes, babies’ neonatal notes, deliv-
ery registers, nursing Kardex, and cot tags;
. limitations in storage space resulted in older records in some
hospitals being destroyed or stored in ways that made them ea-
sily identifiable for destruction, but difficult to access for re-
search;
. when a written record confirming administration is made, the
route (oral or I.M.) is not always specified, especially when nor-
mal hospital practice is to administer vitamin K by a single
route.
These difﬁculties led some researchers to follow the Bristol
group’s lead and impute information about vitamin K prophylaxis
from knowledge of hospital policy. However, whilst all those inves-
tigating this topic appear to concur that route of administration
could often be reliably imputed when vitamin K was recorded as
given but the route was missing, a variety of approaches were
adopted when no record of vitamin K administration was found
in medical notes – the options ranging from assuming that when
no record was found vitamin K was not given, to using clinical
details such as perinatal morbidity to impute whether or not vita-
min K was likely to have been given. Although the validity of using
these different imputation rubrics to assess exposure has been the
subject of much debate, they have never been formally investigated.
Recently reported ﬁndings suggest that in the UK vitamin K poli-
cies may not be a sound basis for imputation, as hospital policies
are not always followed (Ansell et al, 2001).
In summary, our ﬁndings suggest that neonates with a written
record of having received I.M. vitamin K are no more likely to
develop leukaemia, or any other cancer, before their 15th birthday
than neonates without a written record of having received I.M.
vitamin K. The reasons why statistically signiﬁcant increases
emerged when those for whom no written record was found had
their exposure imputed on the basis of perinatal morbidity and
hospital policy are unclear. The pooled adjusted odds ratio for
leukaemia increased from 1.09 (0.92–1.28) when it was assumed
that neonates for whom a written record of I.M. vitamin K was
not found did not have it, to 1.21 (1.02–1.44) when the vitamin
K status of neonates for whom a written record was not found
was inferred from hospital policy and perinatal morbidity. This
shift did not occur in all studies, and when data from the hypoth-
esis generating Bristol study (Golding et al, 1992) were excluded,
the adjusted odds ratios for leukaemia became 1.06 (0.89–1.25)
when the analysis was based on evidence from medical notes and
1.16 (0.97–1.39) when data on prophylaxis imputed from hospital
policy and perinatal morbidity were added. We conclude that the
analysis of the pooled data provide no convincing evidence that
I.M. vitamin K is associated with childhood leukaemia. These ﬁnd-
ings are in broad agreement with two other large investigations,
whose designs differed from those included in the present pooled
analysis (Ekelund et al, 1993; Olsen et al, 1994). In addition, good
quality obstetric data on over 2000 children with cancer and twice
as many unaffected children have been assembled as part of the
United Kingdom Childhood Cancer Study (United Kingdom
Childhood Cancer Study Investigators, 2000). The ﬁndings from
this comprehensive population-based national study should
provide additional insight.
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Table 6 Odds ratios (OR) and 95% conﬁdence intervals (CI) for intramuscular vitamin K, adjusted for mode of delivery, admission
to special care baby unit and low birth weight, following stratiﬁcation by hospital of birth in the total dataset and in the four hospital
based studies only
Recorded in notes with route imputed,
if missing
c
Recorded in notes with route and
administration imputed, if missing
c
Total available data
c Hospital studies only
c,d Total available data
c Hospital studies only
c,d
OR
a (95% CI) OR
a (95% CI) OR
a (95% CI) OR
a (95% CI)
Pooled data
Total cancers 1.06 (0.91–1.24) 1.06 (0.89–1.27) 1.16 (0.96–1.39) 1.11 (0.90–1.37)
Leukaemia 1.12 (0.88–1.41) 1.10 (0.84–1.44) 1.25 (0.94–1.65) 1.17 (0.84–1.62)
ALL
b diagnosed 12–71 months 1.02 (0.76–1.37) 1.03 (0.73–1.45) 1.16 (0.81–1.67) 1.14 (0.74–1.76)
Total minus leukaemia 1.02 (0.84–1.23) 1.04 (0.84–1.28) 1.12 (0.89–1.41) 1.11 (0.86–1.43)
Pooled data – excluding the Bristol study
Total cancers 1.04 (0.89–1.23) 1.04 (0.87–1.26) 1.11 (0.91–1.34) 1.04 (0.83–1.31)
Leukaemia 1.09 (0.85–1.39) 1.06 (0.79–1.41) 1.16 (0.87–1.55) 1.04 (0.73–1.49)
ALL
b diagnosed 12–71 months 0.98 (0.72–1.34) 0.98 (0.68–1.40) 1.09 (0.75–1.59) 1.04 (0.66–1.65)
Total minus leukaemia 1.00 (0.82–1.22) 1.02 (0.82–1.28) 1.08 (0.85–1.38) 1.07 (0.81–1.40)
aOdds ratios and 95% conﬁdence intervals calculated using conditional logistic regression (frequency matched on year of birth, sex and study centre).
bAcute lymphoblastic leukaemia.
cExcludes 335 cases and 1190 controls with no corresponding cases/controls within the strata: Bristol, 49 controls;
Mainz, 202 cases, 267 controls; Oxford ICRF, two controls; Oxford CCRG, two cases; Scotland, 115 cases, 332 controls; Newcastle, 16 cases, 540
controls.
dExcludes data from Mainz and Scotland.
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